3/27
04:00 pm
atyr
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/26
08:00 am
atyr
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
High
Report
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
3/14
03:12 pm
atyr
aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating [Seeking Alpha]
Low
Report
aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating [Seeking Alpha]
3/14
08:04 am
atyr
Atyr PHARMA INC (NASDAQ: ATYR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Low
Report
Atyr PHARMA INC (NASDAQ: ATYR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
3/13
08:07 pm
atyr
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update [Yahoo! Finance]
3/13
04:01 pm
atyr
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
Low
Report
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
3/12
04:00 pm
atyr
aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine
High
Report
aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine
3/6
04:02 pm
atyr
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
High
Report
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
3/4
08:00 am
atyr
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
Medium
Report
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
2/24
08:00 am
atyr
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
High
Report
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
2/19
06:31 am
atyr
Atyr PHARMA INC (NASDAQ: ATYR) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Medium
Report
Atyr PHARMA INC (NASDAQ: ATYR) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
2/18
07:37 am
atyr
Atyr PHARMA INC (NASDAQ: ATYR) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $16.00 price target on the stock.
Medium
Report
Atyr PHARMA INC (NASDAQ: ATYR) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $16.00 price target on the stock.
1/29
08:00 am
atyr
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
Medium
Report
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
1/6
09:33 am
atyr
Atyr PHARMA INC (NASDAQ: ATYR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Medium
Report
Atyr PHARMA INC (NASDAQ: ATYR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.